Gut microbiome and pancreatic cancer cachexia: An evolving relationship.
Cachexia
Gut microbiome
Inflammation
Pancreatic cancer
Stool
Weight
Journal
World journal of gastrointestinal oncology
ISSN: 1948-5204
Titre abrégé: World J Gastrointest Oncol
Pays: China
ID NLM: 101532470
Informations de publication
Date de publication:
15 Jul 2022
15 Jul 2022
Historique:
received:
03
03
2022
revised:
10
05
2022
accepted:
20
06
2022
entrez:
2
9
2022
pubmed:
3
9
2022
medline:
3
9
2022
Statut:
ppublish
Résumé
Nearly 80% of patients with pancreatic ductal adenocarcinoma (PDAC) develop cachexia along their disease course. Cachexia is characterized by progressive weight loss, muscle wasting, and systemic inflammation and has been linked to poorer outcomes and impairments in quality of life. Management of PDAC cachexia has historically involved a multidisciplinary effort comprised of nutritional support, pancreatic enzyme replacement therapy, and/or pharmacologic interventions. Despite current interventions to mitigate PDAC cachexia, a significant proportion of patients continue to die from complications associated with cachexia underscoring the need for novel insights and treatments for this syndrome. We highlight the feasibility and effectiveness of a recent enteral feeding prospective trial at our institution to improve cachexia outcomes in patients with advanced PDAC. Additionally, we were among the first to characterize the stool microbiome composition in patients with advanced PDAC receiving enteral feeding for the treatment of cachexia. Novel insights into the relationship between enteral nutritional support, cachexia, and the gut microbiome are presented. These promising results are discussed in the context of a potential ability to modulate the stool microbiome as a new interventional strategy to mitigate PDAC cachexia.
Identifiants
pubmed: 36051103
doi: 10.4251/wjgo.v14.i7.1218
pmc: PMC9305570
doi:
Types de publication
Editorial
Langues
eng
Pagination
1218-1226Subventions
Organisme : CSRD VA
ID : IK2 CX001717
Pays : United States
Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Références
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Oncologist. 2019 May;24(5):691-701
pubmed: 30591550
Best Pract Res Clin Endocrinol Metab. 2021 May;35(3):101508
pubmed: 33648847
PLoS One. 2015 Jun 22;10(6):e0131009
pubmed: 26098097
Microbiology (Reading). 2021 Oct;167(10):
pubmed: 34596506
World J Gastroenterol. 2020 Dec 28;26(48):7679-7692
pubmed: 33505144
Carcinogenesis. 2020 Jul 10;41(5):561-570
pubmed: 31369062
Int J Med Microbiol. 2020 May;310(4):151425
pubmed: 32423739
ISME J. 2021 Nov;15(11):3207-3220
pubmed: 34002024
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Front Physiol. 2014 Mar 03;5:88
pubmed: 24624094
Mil Med Res. 2015 May 19;2:12
pubmed: 26045969
Am J Clin Nutr. 2006 Jun;83(6):1345-50
pubmed: 16762946
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1959-1968
pubmed: 34609081
PLoS One. 2012;7(6):e37971
pubmed: 22761662
Int J Environ Res Public Health. 2020 Oct 19;17(20):
pubmed: 33086688
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2007-2021
pubmed: 34609073
Proc Nutr Soc. 2015 Nov;74(4):348-54
pubmed: 25809872
Gut Microbes. 2017 Jan 2;8(1):1-16
pubmed: 27874308
Intensive Care Med. 2019 Nov;45(11):1629-1631
pubmed: 31531714
Mol Clin Oncol. 2016 Mar;4(3):315-325
pubmed: 26998283
J Gastrointest Oncol. 2018 Feb;9(1):17-23
pubmed: 29564167
J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):1393-1407
pubmed: 34523250
Nat Med. 2019 Jul;25(7):1104-1109
pubmed: 31235964
Clin Cancer Res. 2021 Jul 1;27(13):3784-3792
pubmed: 33883174
Therap Adv Gastroenterol. 2020 Dec 10;13:1756284820964319
pubmed: 33354227
Front Cell Infect Microbiol. 2019 Sep 12;9:305
pubmed: 31572686